Directory · CH
Biotechnology Research in Switzerland
A register of firms and the professionals working at them in the Biotechnology Research sector based in Switzerland. Browse the public index, then filter or export on Kipplo.
Companies
603 on file
Selexis Sa
KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings.
1001 to 5000 staff
Promega Corporation
At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems. Interactions with our customers, partners and vendors are central to everything we do, and we value those relationships. We seek out and build connections across the globe and in our local communities because creative problem solving requires a network of diverse ideas and viewpoints. We develop and evolve technologies and instrumentation in collaboration with scientists and researchers around the globe. From simple cloning vectors used to address fundamental questions in biology to bioluminescent assays that help us monitor food safety and water quality, we work side-by-side with our partners in academic, industrial and government institutions to bring the best minds to bear on the toughest questions. Since 1978, we have done this all with a steadfast commitment to sustainable business models that protect our environment, inspire and develop our employees as individuals, support the wellbeing and growth of our communities, and strengthen our relationships with our customers. With 16 branches around the world, Promega products are used by a global community of life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification.
1001 to 5000 staff
Tecan
At Tecan we are driven to improve people’s lives and health. We do this by empowering our customers to scale healthcare innovation globally from life science to the clinic. We collaborate with our customers in healthcare and the life sciences, from early-stage innovation through project implementation and beyond. We deliver the products, services and solutions that make lab processes and medical procedures precise, reproducible and compliant. This leads to scalable outcomes that are further reaching and ever more valuable to humankind.
1001 to 5000 staff
Basilea Pharmaceutica
Basilea is a commercial-stage biopharmaceutical company founded in and headquartered in the heart of the life sciences hub of Basel area, Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea currently has about 150 employees and is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
51 to 200 staff
Ac Immune
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.
51 to 200 staff
Bigomics Analytics
At BigOmics, we are committed to empowering researchers in omics data analysis. Our Omics Playground is an intelligent omics data analysis platform that empowers biotech, pharma and academic teams to efficiently perform complex analysis and visualization. Why Omics Playground- Centralized and Searchable Data Management: Seamlessly manage and compare multiple datasets, accelerating discovery over time- Standardized, Reproducible Results: Apply consistent statistical frameworks across studies to ensure robust and reliable outcomes- Efficient and Scalable: Analyze large-scale datasets up to 10x faster, dramatically reducing time from raw data to insight- Publication-Ready Visuals: Export high-quality, customizable figures perfect for presentations, publications, and team collaboration. Governed self-service bioinformatics provides you with a powerful solution to fast-track your bioinformatics needs.
11 to 50 staff
Haelixa
Haelixa is a Swiss deep tech company and ETH Zurich spin-off, founded in 2016 to solve a problem that documentation alone cannot: proving what a product actually is. Counterfeiting costs the luxury industry an estimated $250 billion annually. Sustainability claims in global supply chains are rarely verified at material level. In both cases, the gap between what is claimed and what can be proven is where trust erodes. Haelixa closes that gap with a single technology: patented DNA markers, invisible and harmless, embedded directly into the product at material level. The marker is highly secure and cannot be removed, copied, or altered. ™ is Haelixa's anti-counterfeiting solution for luxury goods - watches, jewellery, and leather. Forensic proof of authenticity that travels with the object across its entire lifecycle. ™ is Haelixa's traceability solution for global supply chains - applied to organic cotton, cashmere, recycled fibres, and next-gen materials. Compliant with GOTS and Oeko-Tex 100. Integrated with Textile Genesis and TrusTrace. 66 million products traced. €2.5 billion in verified sales value. Trusted by brands including Gübelin, Provenance Proof and C&A. Blockchain records a claim. We verify the object.
11 to 50 staff
Kuhner Shaker
Kuhner AG is the leading developer and manufacturer of shaking machines for the international market. Founded in 1949 by Mr Adolf Kühner, this family business is now led by his son Markus Kühner. From bench top shakers to large scale industrial shakers, Kuhner offers machines of the highest quality. We endeavour to understand your science and cultivation needs to ensure solutions accelerating your time to market and elevating your results. We commit to earning the trust of our clients and establishing relationships which will span decades. Alongside the core shaker business, Kuhner AG is also a distributor for premium brands of laboratory equipment in Switzerland.
51 to 200 staff
Molecular Partners
Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA.
51 to 200 staff
Nemis Technologies
The NEMIS approach: Open standards. Global reach. Local proof. NEMIS connects with the systems you already use,and the partners you'll work with tomorrow. Open architecture, shared protocols, proof that travels across borders. Food safety is built on three pillars. Rapid testing that catches contamination early. Transparency and traceability through aggregated data. A people-first culture that shapes behavior—from local kitchens to global standards.
11 to 50 staff
Accelsiors Cro
Accelsiors is an end-to-end clinical research organization that has empowered biopharmaceutical companies for over two decades. We specialize in delivering rapid, cost-effective clinical trial services that drive results. Our commitment extends beyond mere support; we equip our partners with essential scientific advisory, clinical-research regulatory guidance, legal consultancy, and functional service solutions to meet their development targets. With expertise spanning a wide range of therapeutic areas, we provide tailored study design and management from early to late phase, worldwide. Ready to accelerate your drug development journey? Partner with Accelsiors for precision, reliability, and unmatched performance in clinical research. Your success isn’t just our goal—it’s our mission.
201 to 500 staff
Cytosurge
Cytosurge drives the revolution in #SameCell Biology. With our proprietary FluidFM® technology, we provide the world's only platform to physically access, perturb, and profile the same living cell over time, empowering scientists to read, write, and analyze life as it unfolds. FluidFM OMNIUM: The platform for Same-Cell analysis.> Temporal Profiling: Perform non-destructive cytoplasmic biopsies for RNA-seq to track how baseline states causally drive future behavior. Move beyond snapshot correlations to true mechanistic understanding.> Mechanobiology: Leverage precise force control to measure adhesion, stiffness, and mechanical properties at the single-cell level. CellEDIT Service: Powered by FluidFM, vector-free, stoichiometrically controlled CRISPR engineering. We deliver precise, multiplex edits without viral toxicity—even in hard-to-transfect cells. You name it, we edit it.#SameCellBiology #FluidFM #TemporalProfiling #LiveSeq #scRNAseq #Mechanobiology #CRISPR #GeneEditing #Biotech #CellEDIT
11 to 50 staff
Gain Therapeutics
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
11 to 50 staff
Kiniksa Pharmaceuticals
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. At Kiniksa, patients are at the heart of everything we do. Our Every Second Counts! mindset reflects our commitment to making a difference for people who are navigating the uncertainty and challenges of life-altering diseases. This is why our team is relentless in pursuing treatments that bring us closer to a better future for patients, every second of every day. We rely on an exceptional team to drive our mission of building a global, generational company. If you're passionate about making a meaningful impact, we’d love to hear from you. Kiniksa offers competitive benefits and dynamic career opportunities across our organization. We foster a culture of passion, innovation, and rapid execution to help fulfill our mission.
201 to 500 staff
Nanolive Sa
Nanolive: Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics. Nanolive delivers breakthrough 3D imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine screening, imaging and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.
51 to 200 staff
Asceneuron Sa
Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc.(JJDC) and Kurma Partners. For more information, please visit Further information:
1 to 10 staff
Biognosys
The Biognosys Group brings together the Bruker Corporation affiliates Biognosys, biocrates, and PreOmics to deliver integrated solutions across proteomics, metabolomics, and lipidomics. The Group enables seamlessly connected mass spectrometry workflows, making advanced multiomics technologies accessible to laboratories worldwide. Its ecosystem spans high quality consumables, kits, software, and contract research services. Committed to a vendor neutral approach, the Biognosys Group supports open collaboration and broad compatibility across leading mass spectrometry platforms. All solutions are modular by design, allowing customers to choose the level of support that best fits their needs, from ready to use kits and software to guided implementation, or fully integrated end to end CRO services.
51 to 200 staff
Bionomous
Bionomous - the world's first provider of AI-powered solutions for screening, sorting and dispensing of small biological entities. We are an innovative, agile and conscious team of biologists and engineers working to provide you with an easy-to-use and customizable solution to free up valuable time and increase efficiency. Our patented technology was originally created to enable the mechanical sorting of zebrafish eggs. Now, we have adapted this technology to other small biological entities, such as other fish species used in research (killifish, medaka) and aquaculture, plant seeds and 3D cell constructs. Discover how we're automating tomorrow's biology on our website!
11 to 50 staff
Cutiss Ag
CUTISS is a late-stage clinical TechBio company and the only one transforming skin surgery and advanced dermatology with revolutionary skin tissue therapeutics. We are developing the first BIO personalized and automated skin tissue therapy for patients requiring skin surgery for a large spectrum of indications- from severe burns to reconstructive and aesthetic procedures. Our lead product denovoSkin™ is a first-in-class, bioengineered, personalized skin tissue therapy designed to improve patient outcomes and redefine the standard of care in skin surgery. Currently in Phase 3 clinical trials in the European Union, it has Orphan Drug Designation for the treatment of burns from Swissmedic, the EMA, and the US FDA. CUTISS is also pioneering the TECH automation of skin tissue bioengineering, developing the world’s first machine capable of fully automating the manufacturing process. This breakthrough ensures scalability, accessibility and cost-efficiency, and supports attractive unit economics. Our proprietary TECHBIO platform offers growth opportunities in other areas of regenerative medicine, from space research to non-healthcare applications (tissues for industry). Established in 2017, CUTISS is a spin-off from University of Zurich (UZH) and University Children’s Hospital. Headquartered at the Bio-Technopark in Zurich, CUTISS won the Top 100 Swiss Startup Award 2020, and has raised over $90 million from private investors, family offices and public bodies.
11 to 50 staff
Eucodis Bioscience- Biosynth
Eucodis Bioscience is now Biosynth. Securing Life Sciences Supply Chains - where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation.
11 to 50 staff
Fasteris
DNA sequencing service provider based in Geneva, Switzerland. One of the longest experience in illumina Next-Generation DNA sequencing (NGS): L. Farinelli is co-inventor of DNA clusters (1996) and Fasteris was the first service provider in the world to acquire an illumina (then Solexa) sequencer in 2006. The company now uses PacBio Sequel IIe, illumina MiSeq, NextSeq and NovaSeq as well as ThermoFisher's Ion S5. Since 2007, Fasteris developed a broad range of applications to analyze genomes and transcriptomes, from library preparation to bioinformatics analyses- whole genome sequencing, de novo assembly- targeted re-sequencing and exomes- transcriptomes: ISO-seq and stranded RNA protocols- small RNAs- ChIP-SEQ to study protein-DNA binding sites- metagenomics: metabarcoding and full length 16S rRNA- short and long amplicons sequencing- custom projects such as Trypanosoma splice leader, phage display, etc. Genesupport SA, for Life Sciences Fasteris NGS services, provides ISO-17025 services for research laboratories, from small-scale projects to thousands of samples using automated protocols. We produced many thousands of NGS analyses under medical diagnostics conditions and ISO15189 accreditation. In 2013, Fasteris joined the Medisupport and in 2015 Medisupport joined Sonic Healthcare. In 2020 Fasteris merged with Medisupport Genetics labs to create Genesupport SA. Fasteris is the brand for Life Sciences, while Genesupport is used for Medical Genetics. Fasteris is co-author of tens of publications and cited in hundreds, see our website.
51 to 200 staff
Hedera Dx
Hedera Dx enables health systems, patients and drug development programs to easily adopt advanced molecular testing and real-world evidence (RWE) capabilities. Join us on hederadx.com to learn more!
11 to 50 staff
Helvetica Health Care
Helvetica Health Care supply high quality biotechnology products with an unrivaled delivery service to all over the world from our distribution center in Geneva (Switzerland). Our company is ISO 13485:2016 certified. We have many years trading experience with all continents and have developed an important network of contacts. This allows us to provide the best commercial and technical support to our customers and offer shipping and delivery services to any destination with the guarantee of effective control and monitoring services.
1 to 10 staff
Hse Ag
HSE•AG: Engineering Precision for Life Science Innovation At HSE•AG, we empower breakthrough discoveries in life science and diagnostics by delivering tailored, high-performance engineering solutions. From concept to market, we partner with leading companies to transform complex biological workflows into scalable, automated systems. Our Expertise Includes- Laboratory automation and system integration - OEM product development and industrialization - Mechanical and software engineering - Instruments, software and consumable development - Life cycle and risk management - Application-driven design and concepts We bridge biological insight with engineering excellence, designing technologies that accelerate discovery, improve reproducibility, and streamline diagnostics. Our solutions are optimized for real-world use in research labs, diagnostic settings, and manufacturing environments. At HSE•AG, we don’t just solve engineering problems—we help you create measurable impact. Let’s shape the future of life sciences, together.
51 to 200 staff
